...
search icon
prta-img

Prothena Corporation plc, Common Stock

PRTA

NSQ

$4.58

-$2

(-30.4%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$392.40M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
9.65M
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.10
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$6.36 L
$25.42 H
$4.58

About Prothena Corporation plc, Common Stock

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. Its product pipeline includes birtamimab, an investigational humanized antibody, which in phase 3 clinical trial to treat patients with AL amyloidosis; and Prasinezumab, an investigational humanized monoclonal antibody which is in phase 2b clinical trial, as well as phase 1 and 2 clinical trials for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in phase 2 clinical trial for potential treatment of transthyretin amyloidosis; BMS-986446, an investigational antibody, which is in phase 2 clinical trial to treat Alzheimer's disease; PRX012, an investigational antibody, which is in phase 1 clinical trial to treat Alzheimer's disease; PRX123, a Dual Aß-Tau Vaccine, which is in preclinical trial for treating Alzheimer's disease; and PRX019, an investigational antibody, which is in phase 1 clinical trial for the potential treatment of neurodegenerative diseases. It has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and master collaboration agreement with Bristol Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. Prothena Corporation plc was incorporated in 2012 and is based in Dublin, Ireland. more

Industry: BiotechnologySector: Health Care

Returns

Time FramePRTASectorS&P500
1-Week Return-37.17%-3.24%-2.29%
1-Month Return-52.54%-5.96%5.13%
3-Month Return-69.73%-11.47%-1.04%
6-Month Return-71.16%-11.3%-3.3%
1-Year Return-77.04%-8.64%9.3%
3-Year Return-83.75%-2.75%39.44%
5-Year Return-60.31%29.73%90.79%
10-Year Return-86.45%73.6%173.11%

Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue853.00K200.58M53.91M91.37M135.16M[{"date":"2020-12-31","value":0.43,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":26.87,"profit":true},{"date":"2023-12-31","value":45.55,"profit":true},{"date":"2024-12-31","value":67.38,"profit":true}]
Cost of Revenue74.88M82.28M6.74M220.57M3.58M[{"date":"2020-12-31","value":33.95,"profit":true},{"date":"2021-12-31","value":37.3,"profit":true},{"date":"2022-12-31","value":3.06,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":1.63,"profit":true}]
Gross Profit853.00K200.58M53.91M(129.20M)131.57M[{"date":"2020-12-31","value":0.43,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":26.87,"profit":true},{"date":"2023-12-31","value":-64.41,"profit":false},{"date":"2024-12-31","value":65.6,"profit":true}]
Gross Margin100.00%100.00%100.00%(141.40%)97.35%[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-141.4,"profit":false},{"date":"2024-12-31","value":97.35,"profit":true}]
Operating Expenses113.59M128.60M185.46M282.41M289.72M[{"date":"2020-12-31","value":39.21,"profit":true},{"date":"2021-12-31","value":44.39,"profit":true},{"date":"2022-12-31","value":64.01,"profit":true},{"date":"2023-12-31","value":97.48,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Operating Income(112.73M)71.97M(131.56M)(191.04M)(154.56M)[{"date":"2020-12-31","value":-156.63,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-182.78,"profit":false},{"date":"2023-12-31","value":-265.42,"profit":false},{"date":"2024-12-31","value":-214.74,"profit":false}]
Total Non-Operating Income/Expense2.68M(12.00K)12.30M61.57M51.45M[{"date":"2020-12-31","value":4.35,"profit":true},{"date":"2021-12-31","value":-0.02,"profit":false},{"date":"2022-12-31","value":19.98,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":83.56,"profit":true}]
Pre-Tax Income(111.43M)71.92M(125.61M)(160.48M)(128.93M)[{"date":"2020-12-31","value":-154.93,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-174.64,"profit":false},{"date":"2023-12-31","value":-223.13,"profit":false},{"date":"2024-12-31","value":-179.27,"profit":false}]
Income Taxes(283.00K)4.95M(8.66M)(13.45M)(6.62M)[{"date":"2020-12-31","value":-5.72,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-175.01,"profit":false},{"date":"2023-12-31","value":-271.98,"profit":false},{"date":"2024-12-31","value":-133.85,"profit":false}]
Income After Taxes(111.14M)66.97M(116.95M)(147.03M)(122.31M)[{"date":"2020-12-31","value":-165.95,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-174.62,"profit":false},{"date":"2023-12-31","value":-219.53,"profit":false},{"date":"2024-12-31","value":-182.62,"profit":false}]
Income From Continuous Operations(111.14M)66.97M(116.95M)(147.03M)(122.31M)[{"date":"2020-12-31","value":-165.95,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-174.62,"profit":false},{"date":"2023-12-31","value":-219.53,"profit":false},{"date":"2024-12-31","value":-182.62,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(111.14M)66.97M(116.95M)(147.03M)(122.31M)[{"date":"2020-12-31","value":-165.95,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-174.62,"profit":false},{"date":"2023-12-31","value":-219.53,"profit":false},{"date":"2024-12-31","value":-182.62,"profit":false}]
EPS (Diluted)(2.79)1.09(2.51)(2.80)(2.30)[{"date":"2020-12-31","value":-255.96,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-230.28,"profit":false},{"date":"2023-12-31","value":-256.88,"profit":false},{"date":"2024-12-31","value":-211.01,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

PRTA
Cash Ratio 8.62
Current Ratio 9.00

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

PRTA
ROA (LTM) -15.49%
ROE (LTM) -23.46%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

PRTA
Debt Ratio Lower is generally better. Negative is bad. 0.12
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.88

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

PRTA
Trailing PE NM
Forward PE 64.10
P/S (TTM) 2.57
P/B 0.81
Price/FCF NM
EV/R 2.82
EV/Ebitda NM
PEG 0.80

FAQs

What is Prothena Corporation plc share price today?

Prothena Corporation plc (PRTA) share price today is $4.58

Can Indians buy Prothena Corporation plc shares?

Yes, Indians can buy shares of Prothena Corporation plc (PRTA) on Vested. To buy Prothena Corporation plc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in PRTA stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Prothena Corporation plc be purchased?

Yes, you can purchase fractional shares of Prothena Corporation plc (PRTA) via the Vested app. You can start investing in Prothena Corporation plc (PRTA) with a minimum investment of $1.

How to invest in Prothena Corporation plc shares from India?

You can invest in shares of Prothena Corporation plc (PRTA) via Vested in three simple steps:

  • Click on Sign Up or Invest in PRTA stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Prothena Corporation plc shares
What is Prothena Corporation plc 52-week high and low stock price?

The 52-week high price of Prothena Corporation plc (PRTA) is $25.42. The 52-week low price of Prothena Corporation plc (PRTA) is $6.36.

What is Prothena Corporation plc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Prothena Corporation plc (PRTA) is 0.81

What is the Market Cap of Prothena Corporation plc?

The market capitalization of Prothena Corporation plc (PRTA) is $392.40M

What is Prothena Corporation plc’s stock symbol?

The stock symbol (or ticker) of Prothena Corporation plc is PRTA

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top